The cause of the downregulation of MHC-II was suggested to be FOXP1 acting as a novel negative regulator of CIITA target genes; thus, suppression of FOXP1 could represent a therapeutic target for the treatment of DLBCL [133]. This evidence concerns the gene CIITA and diffuse large B-cell lymphoma.